Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 14/20 | 0.50 |
| ▸ | F13A1 | P00488 | 11/20 | 0.50 |
| ▸ | TGM1 | P22735 | 8/20 | 0.50 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12662170 | 0.84 | STS (0.54) | STSMAPT | |
| SCHEMBL28919020 | 0.83 | STS (0.63) | TGM2F13A1TGM1TGM3STS | |
| SCHEMBL6564154 | 0.82 | TGM2 (0.49) | TGM2F13A1TGM1TGM3STS | |
| SCHEMBL17293336 | 0.82 | STS (0.47) | TGM2F13A1TGM1TGM3STS | |
| SCHEMBL10077622 | 0.82 | STS (0.45) | TGM2F13A1TGM1STS | |
| SCHEMBL12662189 | 0.81 | STS (0.46) | TGM2F13A1TGM1STS | |
| SCHEMBL6565749 | 0.80 | TGFBR1 (0.54) | STSMAPT | |
| SCHEMBL12662192 | 0.80 | CXCR2 (0.50) | STS | |
| SCHEMBL12662263 | 0.80 | CXCR2 (0.50) | STS | |
| SCHEMBL5738625 | 0.80 | TGM2 (0.56) | TGM2F13A1TGM1TGM3STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2388006-A1 | Urea derivatives as IL-8 receptor antagonists | GlaxoSmithKline LLC (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20110253866-A1 | SWINGING SUPPORT DEVICE | PANASONIC CORPORATION (JP) | 2011-10-20 | — | — | US | disclosed |
| US-20100256157-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100256157-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE LLC | 2010-10-07 | — | — | US | disclosed |
| EP-2203432-A1 | METHOD OF TREATMENT | GlaxoSmithKline LLC (US) | 2010-07-07 | — | — | EP | disclosed |
| US-7709485-B2 | IL-8 receptor antagonists | GLAXOSMITHKLINE LLC (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090281110-A1 | Method of Treatment | SMITHKLINE BEECHAM CORPORATION | 2009-11-12 | — | — | US | disclosed |
| US-20090281110-A1 | Method of Treatment | SMITHKLINE BEECHAM CORPORATION | 2009-11-12 | — | — | US | disclosed |
| EP-2032131-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2009-09-02 | — | — | EP | disclosed |
| US-20090170871-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-02 | — | — | US | disclosed |
| WO-2004039775-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-13 | — | — | WO | disclosed |
| EP-1161232-B1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20040048897-A1 | Il-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-03-11 | — | — | US | disclosed |
| EP-1351933-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-06-12 | — | — | US | disclosed |
| US-6500863-B1 | INTERLEUKIN BINDING INHIBITORS SUCH AS N-(2-HYDROXYL-3-AMINO SULFONYL-4-CHLOROPHENYL)-N'-(2-BROMOPHENYL)UREA, USED FOR PROPHYLAXIS OF CHEMOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2002-12-31 | — | — | US | disclosed |
| EP-1161232-A4 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-09-18 | — | — | EP | disclosed |
| WO-2002057230-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-07-25 | — | — | WO | disclosed |
| EP-1161232-A1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000035442-A1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256157-A1 | METHOD OF TREATMENT | CFTR, CTH, TST | TGM2 136/4885F13A1 4114/4885TGM1 214/4885 |
| US-20040048897-A1 | Il-8 receptor antagonists | CXCL8, CCR8, TLR8 | TGM2 2325/4885F13A1 797/4885TGM1 2546/4885 |
| US-20090281110-A1 | Method of Treatment | ESR2, CTH, SULT2A1 | TGM2 595/4885F13A1 4240/4885TGM1 1116/4885 |
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | CXCL8, CCR8, IL18 | TGM2 2515/4885F13A1 3687/4885TGM1 3244/4885 |
| US-20090170871-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | TGM2 2348/4885F13A1 1247/4885TGM1 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.